Role of selective pulmonary vasodilators in management of hypertensive ventricular septal defect in pediatrics | ||||
| Benha Journal of Applied Sciences | ||||
| Article 4, Volume 6, Issue 5, September 2021, Page 21-26 PDF (299.18 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2021.198192 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| I.M. Kasab; M.E. Rezk; B.M. Aglan; M.A. Saleh | ||||
| Cardiothoracic surgery, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Background: Septal ventricular defect is an acyanotic heart condition that requires operation. Pulmonary artery pressure is a major determinant in the outcome of surgery Objectives: Evaluation of the usage of antihypertensive pulmonary medicines after surgical closure of septal ventricular hypertension defects. Materials: 60 patients were chosen for primary ventricular septal defect surgical repair. Instances with congenital abnormalities were eliminated rather than PDA or ASD and redo cases. These cases were divided into two groups (each of 30 patients) one with oral sildenafil and the other with no oral sildenafil. Results: The mean pulmonary artery pressure of sildenafil dropped from 66.4 ± 9.1 to 42.5 ± 3.6 mmHg and decreased to 50.2 ± 5.3 mmHg in the control group. Conclusion: Pulmonary antihypertensive medicines have an essential role in reducing pulmonary artery pressure and provide improved surgical outcomes. | ||||
| Keywords | ||||
| Ventricular septal defect; pulmonary hypertension; pulmonary vasodilators | ||||
|
Statistics Article View: 101 PDF Download: 233 |
||||
